mAbxience |

European Commission Approves mAbxience’s Bevacizumab For The Treatment Of Certain Types Of Cancer

03/31/2021

The European Commission (EC) has approved mAbxience’s MB02 biosimilar to Avastin® (Bevacizumab), in Europe.

Spain’s mAbxience boosting biologics capacity with 4,000 L SUB

03/25/2021

Biosimilar maker and CDMO mAbxience will install an ABEC 4,000 L CSR bioreactor at its site in León, Spain. mAbxience, the biologics division of Spain’s Insud Pharma group, claims its León plant is “the biggest biologic plant in Spain and the first in Europe with fully integrated single-use technology in most processes.” Now the site […]

ESMO publication: EMA grants a marketing authorisation for two biosimilar medicines, bevacizumab

02/15/2021

They received a positive opinion for the treatment of carcinoma of the colon or rectum, breast cancer, NSCLC, RCC, epithelial ovarian cancer, and carcinoma of the cervix

Bio-Europe Spring 2021

01/22/2021

Meet us at Bio-Europe Spring, to be held 22-25 March. 2021.

Bio 2021

01/22/2021

Meet us at BIO, to be held 14-17 June. 2021.

Spanish group Insud Pharma signs agreement with AstraZeneca to manufacture COVID-19 vaccine candidate

01/20/2021

The plant in Spain’s Castilla-La Mancha region will undertake vial filling and packaging for AZD1222 The company also provides drug substance manufacturing for AZD1222 through their site in Argentina Insud Pharma is at the forefront of Spanish companies in investment in R&D The Spanish pharmaceutical group Insud Pharma will provide vial filling and packaging of […]